Vascular mineralocorticoid receptor activation and disease. (November 2019)

• Record Type: Journal Article
• Authors: Barrera-Chimal, Jonatan; Jaisser, Frederic
• Is Part Of: Experimental eye research. Volume 188(2019)
• Publication Date: 2019-11
• Subjects: Vascular injury -- Aldosterone -- Angiogenesis; Ophthalmology -- Periodicals; Eye -- Periodicals; Œil -- Périodiques; Ophthalmology; Periodicals; Electronic journals; 612.8405
• DOI: 10.1016/j.exer.2019.107796
• Languages: English
• ISSNs: 0014-4835

Abstract

Abstract: Mineralocorticoid receptor activation in endothelial and smooth muscle cells can promote vascular disease by increasing oxidative stress, promoting inflammation, accelerating vascular stiffness, remodeling, and calcification, altering vessel responsiveness to various vasoactive factors, thus altering vascular tone and blood pressure, and by altering angiogenesis. Here, we review the recent evidence highlighting the impact of vascular mineralocorticoid receptor activation in pathological situations, including kidney injury, vascular injury associated with metabolic diseases, atherosclerosis, cerebral vascular injury during hypertension, vascular stiffening and aging, pulmonary hypertension, vascular calcification, cardiac remodeling, wound healing, inflammation, thrombosis, and disorders related to angiogenic defects in the eye. The possible mechanisms implicating mineralocorticoid receptor activation in various vascular disorders are discussed. Altogether, recent evidence points towards pharmacological mineralocorticoid receptor inhibition as a strategy to treat diseases in which overactivation of the mineralocorticoid receptor in endothelial and/or smooth muscle cells may play a pivotal role. Highlights: Vascular MR increases oxidative injury and vascular inflammation. Vascular MR modulates blood pressure and vascular stiffness. Smooth muscle cell MR promotes vascular remodeling and calcification. MR antagonism is beneficial in neovascularization induced eye diseases.